Low-dose aspirin and survival in men with prostate cancer: A study using the UK Clinical Practice Research Datalink

Cancer Causes and Control

Volumn 25, Issue 1, 2014, Pages 33-43

  Cardwell, Chris R ^a   Flahavan, Evelyn M ^b   Hughes, Carmel M ^a   Coleman, Helen G ^a   O'Sullivan, Joe M ^a,c   Powe, Des G ^d,e   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Aspirin; Mortality; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ESTROGEN THERAPY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; UNITED KINGDOM; VERY ELDERLY; CASE CONTROL STUDY; MORTALITY; PROSTATE TUMOR; RISK;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK;

EID: 84893658349     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0306-x     Document Type: Article

References (34)

1. NHS (2011) Prescriptions dispensed in the community, statistics for England - 2000-2010. The NHS Information Centre, Prescribing and Primary Care Services
2. BNF (2012) British National Formulary: current edition. BMJ Group & Pharmaceutical Press, London
3. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373:1301-1309
4. Wu KK (2000) Aspirin and salicylate: an old remedy with a new twist. Circulation 102:2022-2023
5. Pruthi RS, Wallen EM (2005) Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin Genitourin Cancer. 4:203-211
6. Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 61:46-52
7. Nash GF, Turner LF, Scully MF, Kakkar AK (2002) Platelets and cancer. Lancet Oncol. 3:425-430
8. Jain S, Harris J, Ware J (2010) Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 30:2362-2367
9. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T et al (2007) The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170:1337-1347
10. Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9:237-249
11. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
12. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G et al (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-1612
13. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23:1403-1415
14. Norrish AE, Jackson RT, McRae CU (1998) Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77:511-515
15. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC et al (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 11:1108-1111
16. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 128:2444-2452
17. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila). 5:1223-1228
18. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol
19. Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2013) Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol
20. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766-768
21. NCI (2012) SEER training modules, prostate cancer. Morphology & Grade 2012 27/11/2012; Available from: http://training.seer.cancer.gov/prostate/ abstract-code-stage/morphology.html
22. Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11:1
23. Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
24. Etminan M, Samii A (2004) Pharmacoepidemiology I. A review of pharmacoepidemiologic study designs. Pharmacotherapy. 24:964-969
25. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
26. Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phe V, Bitker MO et al (2012) Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 110:E826-E829
27. Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH et al (2009) Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 104:1592-1598
28. Bannon F, Gavin AT (2009) Monitoring care of prostate cancer patients in Northern Ireland diagnosed 2006 (with comparison 1996 & 2001). Northern Ireland Cancer Registry, Belfast
29. Fujisawa M, Miyake H (2008) Significance of micrometastases in prostate cancer. Surg Oncol 17:247-252
30. Cardwell CR, Suissa S, Murray LJ (2013) Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 64:e10
31. Bedson J, Whitehurst T, Lewis M, Croft P (2001) Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 51:1001-1003
32. Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD (2008) Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 17:869-876
33. Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961-968
34. Choe KS, Correa D, Jani AB, Liauw SL (2010) The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 116:1820-1826